+44 (0)20 3910 4640 hello@symmetron.net

juvenile idiopathic arthritis

 

Tocilizumab in polyarticular juvenile idiopathic arthritis: a cost-utility model for the United Kingdom

Value in Health. 2013;16(7):A564

Authors

Chang S, Sawyer L, Dejonckheere F, van Suijlekom-Smit LW, Anink J, Diamantopoulos A

Process

\

An individual sampling model was developed to reflect the health care system and treatment pathway in the UK

\

Utility data were derived from a large national database

\

Costs were calculated from National Health Service reference costs and Personal Social Services perspective

\

Efficacy inputs were derived from an indirect treatment comparison conducted by Symmetron

Publications in other disease areas

Atrial fibrillation

Cost-effectiveness of an insertable cardiac monitor to detect atrial fibrillation in patients with cryptogenic stroke

Cancer

Societal costs of Er+/Her2- advanced or metastatic breast cancer in post-menopausal women in the United Kingdom

Idiopathic pulmonary fibrosis

The burden of illness of idiopathic pulmonary fibrosis: a comprehensive evidence review

Psoriasis

The comparative efficacy of brodalumab in patients with moderate-to-severe psoriasis: a systematic literature review and network meta-analysis

Rheumatoid arthritis

Tocilizumab in the treatment of rheumatoid arthritis: a cost-effectiveness analysis in the UK

 

Venous thromboembolism

Cost-effectiveness of rivaroxaban in the prevention of venous thromboembolism: A Canadian analysis using the Ontario Ministry of Health Perspective